Quick answers
- What is Verapamil hydrochloride used for?
- The FDA-approved label (Verapamil Hydrochloride, Chartwell RX, LLC, March 25, 2025) says: “Verapamil Hydrochloride Extended-release Capsules (PM) for oral use is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Verapamil hydrochloride have a boxed warning?
- No. None of the 92 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Verapamil hydrochloride?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Verapamil hydrochloride been recalled?
- FDA enforcement reports list 3 recalls of products of this medicine; the newest started July 2, 2024 (Class III). A recall usually concerns specific lots, not every product.
- Who makes Verapamil hydrochloride?
- 40 companies list prescription products of Verapamil hydrochloride in the FDA NDC Directory, including Bryant Ranch Prepack, HF Acquisition Co LLC, DBA HealthFirst and Wilshire Pharmaceuticals, Inc..
What Verapamil hydrochloride is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Verapamil Hydrochloride Extended-release Capsules (PM) for oral use is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. …
— FDA label: Verapamil Hydrochloride, Chartwell RX, LLC, effective March 25, 2025. Read the full label on DailyMed →
The FDA has 92 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 92 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet · Injection, solution · Tablet, film coated, extended release · Injection · Capsule, extended release · Tablet, film coated · Capsule, delayed release · Tablet, extended release |
|---|---|
| Route | Oral · Intravenous |
| Prescription products | 134 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| verapamil hydrochloride 100 mg capsule, extended release | Generic | $4.11 per capsule |
| verapamil hydrochloride 120 mg capsule, delayed release | Generic | $2.92 per capsule |
| verapamil hydrochloride 120 mg capsule, extended release | Generic | $2.92 per capsule |
| verapamil hydrochloride 120 mg tablet | Generic | $0.0864–$0.2022 per tablet 3 packages, lowest to highest |
| verapamil hydrochloride 120 mg tablet, film coated | Generic | $0.0864 per tablet |
| verapamil hydrochloride 120 mg tablet, film coated, extended release | Generic | $0.2022 per tablet |
| verapamil hydrochloride 180 mg capsule, delayed release | Generic | $2.83 per capsule |
| verapamil hydrochloride 180 mg capsule, extended release | Generic | $2.83 per capsule |
| verapamil hydrochloride 180 mg tablet | Generic | $0.1944 per tablet |
| verapamil hydrochloride 180 mg tablet, film coated, extended release | Generic | $0.1944 per tablet |
| verapamil hydrochloride 200 mg capsule, extended release | Generic | $5.69 per capsule |
| verapamil hydrochloride 240 mg capsule, delayed release | Generic | $3.43 per capsule |
| verapamil hydrochloride 240 mg capsule, extended release | Generic | $3.43 per capsule |
| verapamil hydrochloride 240 mg tablet | Generic | $0.1916 per tablet |
| verapamil hydrochloride 240 mg tablet, film coated, extended release | Generic | $0.1916 per tablet |
| verapamil hydrochloride 300 mg capsule, extended release | Generic | $7.94 per capsule |
| verapamil hydrochloride 360 mg capsule, delayed release | Generic | $7.61 per capsule |
| verapamil hydrochloride 40 mg tablet | Generic | $0.1123 per tablet |
| verapamil hydrochloride 40 mg tablet, film coated | Generic | $0.1123 per tablet |
| verapamil hydrochloride 80 mg tablet | Generic | $0.0716 per tablet |
| verapamil hydrochloride 80 mg tablet, film coated | Generic | $0.0716 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack8 products
- HF Acquisition Co LLC, DBA HealthFirst8 products
- Wilshire Pharmaceuticals, Inc.7 products
- NuCare Pharmaceuticals, Inc.7 products
- Medical Purchasing Solutions, LLC7 products
- Zydus Pharmaceuticals USA Inc.6 products
- Northwind Health Company, LLC6 products
- Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.5 products
- Zydus Lifesciences Limited5 products
- A-S Medication Solutions5 products
- Remedyrepack Inc.4 products
- Chartwell RX, LLC4 products
- Proficient Rx LP4 products
- Preferred Pharmaceuticals Inc.4 products
- Hospira, Inc.3 products
- Nivagen Pharmaceuticals, Inc.3 products
- AvKARE3 products
- Golden State Medical Supply, Inc.3 products
- Actavis Pharma, Inc.3 products
- Mylan Pharmaceuticals Inc.3 products
- Cadila Pharmaceuticals Limited3 products
- Somerset Therapeutics, LLC3 products
- Glenmark Pharmaceuticals Inc., USA3 products
- Caplin Steriles Limited2 products
- Eugia US LLC2 products
- Gland Pharma Limited2 products
- Lifestar Pharma LLC2 products
- Aphena Pharma Solutions - Tennessee, LLC2 products
- PD-Rx Pharmaceuticals, Inc.2 products
- Exela Pharma Sciences, LLC2 products
- Henry Schein, Inc.2 products
- Armas Pharmaceuticals Inc.2 products
- Amneal Pharmaceuticals LLC2 products
- Baxter Healthcare Corporation2 products
- Mylan Institutional Inc.1 product
- ProPharma Distribution1 product
- Sagent Pharmaceuticals1 product
- Micro Labs Limited1 product
- Safecor Health LLC1 product
- Fresenius Kabi USA, LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA018925 VERAPAMIL HYDROCHLORIDE | Exela Pharma | March 30, 1984 | 10, latest November 18, 2016 2016: Labeling · 2016: Manufacturing (CMC) · 2011: Labeling |
| NDA019614 VERELAN | Azurity | May 29, 1990 | 34, latest October 1, 2019 2019: Labeling · 2016: Labeling · 2014: Labeling |
| NDA020943 VERELAN PM | Azurity | November 25, 1998 | 15, latest October 3, 2019 2019: Labeling · 2016: Labeling · 2014: Labeling |
Generic approvals (23)
- ANDA070994Watson Labs · October 1, 1986
- ANDA070995Watson Labs · October 1, 1986
- ANDA070737Hospira · May 6, 1987
- ANDA070738Hospira · May 6, 1987
- ANDA071881Heritage · April 5, 1988
- ANDA072924Watson Labs · June 29, 1993
- ANDA075136Hospira · October 20, 1998
- ANDA075138Mylan · April 20, 1999
- ANDA078906Glenmark Pharms Ltd · September 17, 2009
- ANDA090700Glenmark Pharms Ltd · August 3, 2011
- ANDA206173Cadila Pharms Ltd · May 5, 2017
- ANDA211015Somerset Theraps LLC · June 18, 2018
- ANDA211035Somerset · June 18, 2018
- ANDA210994Amneal · July 13, 2018
- ANDA211370Micro Labs · December 28, 2018
- ANDA213232Caplin · March 25, 2020
- ANDA212965Eugia Pharma · July 6, 2020
- ANDA214215Zydus Pharms · October 15, 2020
- ANDA214361Gland · October 15, 2020
- ANDA215829Heritage · March 17, 2022
- ANDA214653Mankind Pharma · June 15, 2022
- ANDA216471Fresenius Kabi USA · April 23, 2024
- ANDA219252Zydus Lifesciences · November 24, 2025
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
July 2, 2024 · Class III · Ongoing · D-0593-2024
Cross contamination with other products.
Verapamil Hydrochloride Injection, USP 10 mg/4 mL (2.5 mg/mL), 5 x 4 mL Single-Dose Vial per carton, Rx Only, Manufactured by: Zydus Lifesciences Ltd. Vadodara, India, Distributed by: Zydus Pharmaceuticals (USA)Inc., Pen — Zydus Pharmaceuticals (USA) Inc
-
July 2, 2024 · Class III · Ongoing · D-0592-2024
Cross contamination with other products.
Verapamil Hydrochloride Injection, USP 5 mg / 2mL(2.5 mg/mL), packaged as (a) 25x2 mL Single-Dose Vial per carton, Vial NDC: 70710-1643-1; Carton NDC 70710-1643-7; (b) 5x2 mL Single-Dose Vial per carton, Vial NDC: 70710- — Zydus Pharmaceuticals (USA) Inc
-
March 15, 2021 · Class II · Terminated · D-0483-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Verapamil Hydrochloride Extended-Release Tablets USP 120 mg Rx Only NDC 68462-292-01 Manufactured by: Glenmark Generics Ltd Colvale-Bardez, Goa 403513, India Manufactured for: Glenmark Generics Inc., USA Mahwah, NJ 07430 — Cardinal Health Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Verapamil Hydrochloride, Chartwell RX, LLC, effective March 25, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →